CUREVAC
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer.
CUREVAC
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2000-01-01
Address:
Tübingen, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.curevac.com
Total Employee:
251+
Status:
Active
Contact:
+49707198830
Total Funding:
1.85 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
2019-06-01
Board_member
Board_member
Board_member
Current Employees Featured
Franz-Werner Haas Chief Corporate Officer @ CureVac
Chief Corporate Officer
2012-01-01
Florian von der Mulbe Co-Founder, CPO @ CureVac
Co-Founder, CPO
2018-01-01
Ulrike Gnad-Vogt Chief Medical Officer @ CureVac
Chief Medical Officer
2013-08-01
Nigel Horscroft Area Head - Molecular Therapy @ CureVac
Area Head - Molecular Therapy
2017-01-01
Mariola Fotin-Mleczek Chief Technology Officer @ CureVac
Chief Technology Officer
2018-10-01
George Siber Member of SAB @ CureVac
Member of SAB
2015-01-01
Patrick Baumhof Vice President Formulation & Delivery @ CureVac
Vice President Formulation & Delivery
2017-01-01
Pierre Kemula CFO @ CureVac
CFO
2016-10-01
Steve Pascolo Co-Founder and CSO @ CureVac
Co-Founder and CSO
2000-05-01
Regina Heidenreich Head of Immunotherapy @ CureVac
Head of Immunotherapy
2012-12-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-06-08 | Frame Cancer Therapeutics | Frame Cancer Therapeutics acquired by CureVac | 32 M EUR |
Investors List
German Federal Ministry of Education and Research (BMBF)
German Federal Ministry of Education and Research (BMBF) investment in Grant - CureVac
Qatar Investment Authority
Qatar Investment Authority investment in Venture Round - CureVac
GlaxoSmithKline
GlaxoSmithKline investment in Corporate Round - CureVac
European Investment Bank
European Investment Bank investment in Debt Financing - CureVac
KfW
KfW investment in Venture Round - CureVac
LBBW Asset Management
LBBW Asset Management investment in Series F - CureVac
Baden-Württembergische Versorgungsanstalt für Ärzte
Baden-Württembergische Versorgungsanstalt für Ärzte investment in Series F - CureVac
Landeskreditbank Baden-Württemberg
Landeskreditbank Baden-Württemberg investment in Series F - CureVac
Baillie Gifford
Baillie Gifford investment in Series F - CureVac
Chartwave
Chartwave investment in Series F - CureVac
Key Employee Changes
| Date | New article |
|---|---|
| 2020-08-04 | Curevac names Franz-Werner Haas as CEO |
Official Site Inspections
http://www.curevac.com Semrush global rank: 241.55 K Semrush visits lastest month: 291.99 K
- Host name: dedi3042.your-server.de
- IP address: 188.40.29.42
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "CureVac"
CureVac - Wikipedia
CureVac N.V. is a German biopharmaceutical company. It develops therapies based on messenger RNA (mRNA). Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac has had approximately 375 employees since May 2018. See details»
CureVac - Wir revolutionieren die mRNA für das Leben …
Großaktionäre, die mindestens 5 Prozent einer CureVac-Aktie besitzen, müssen ihre Verkäufe und Käufe der SEC offenlegen. Aktuelle Pressemitteilungen. 12. November 2024. CureVac veröffentlicht Finanzergebnisse für das dritte …See details»
About Us - CureVac
With a single discovery, CureVac opened the world up to the potential of mRNA to treat diseases and create vaccines. Officially founded in 2000, CureVac is the world’s first company to successfully harness mRNA for medical …See details»
CureVac - Crunchbase Company Profile & Funding
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the …See details»
CureVac N.V. (LON: 0A9E) Company Profile & Overview - Stock …
3 days ago CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing …See details»
CureVac N.V. (CVAC) Company Profile & Facts - Yahoo Finance
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic …See details»
CureVac (CureVac AG) - Startbase
Date News; 30.11.2023 06:00: Inside the portfolios of Germany’s tech billionaires The investments of Germany's richest entrepreneurs include biotech giant CureVac and famed startup factory Rocket Internet. Quelle: Sifted.eu: …See details»
CureVac - Simple English Wikipedia, the free encyclopedia
CureVac N.V. is a German biopharmaceutical company that creates therapies based on messenger RNA (mRNA). It is headquartered in Tübingen, Germany.The company was …See details»
CureVac - Funding, Financials, Valuation & Investors - Crunchbase
CureVac is registered under the ticker NASDAQ:CVAC . Their stock opened with $16.00 in its Aug 14, 2020 IPO. CureVac is funded by 16 investors. German Federal Ministry of Education …See details»
CureVac Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 CureVac has 5 employees across 6 locations and €53.76 m in annual revenue in FY 2023. See insights on CureVac including office locations, competitors, revenue, financials, …See details»
CureVac CEO and Key Executive Team | Craft.co
CureVac's Co-Founder is Ingmar Hoerr. Other executives include Pierre Kemula, Chief Financial Officer; Malte Greune, Chief Operating Officer and 2 others. See the full leadership team at Craft.See details»
CureVac AG - Devex
Learn more about CureVac AG's jobs, projects, latest news, contact information and geographical presence. CureVac – Where the Pioneering Spirit Meets Expert KnowledgeLike many …See details»
CureVac - Contacts, Employees, Board Members, Advisors & Alumni
Organization. CureVac . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... CureVac has 14 current employee profiles, including Co-Founder, CPO …See details»
Overview - CureVac
Nov 12, 2024 The Annual General Meeting (the “AGM”) of Shareholders of CureVac N.V. (the “Company”) was held on Thursday, June 24, 2021, at 2:00 p.m. Central European Summer …See details»
CureVac
From day one, people have always been central to CureVac’s mission — after all, we are on a mission to use therapeutic mRNA to transform people’s lives. That’s why we are dedicated to …See details»
CureVac N.V. (LON: 0A9E) Stock Price & Overview - Stock Analysis
Dec 30, 2024 CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing …See details»
CureVac COVID-19 vaccine - Wikipedia
The CureVac COVID-19 vaccine (abbreviated CVnCoV) was a COVID-19 vaccine candidate developed by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI). …See details»
Stellenabbau und Rechtsstreit: Darauf konzentriert sich Curevac jetzt
13 hours ago Curevac, das Biotech-Unternehmen aus Tübingen, richtet sich nach dem gescheiterten Corona-Impfstoff neu aus. Worauf jetzt der Fokus liegt. Tübingen - Das Biotech …See details»
COVID-19 - CureVac
On January 30, 2020, the World Health Organization (WHO) declared the outbreak under International Health Regulations a public health emergency of international concern, which …See details»
Curevac fokussiert sich auf Forschung - cash
11 hours ago Nach Millionenverlusten rund um die gescheiterte Entwicklung eines Corona-Impfstoffs fokussiert sich das Tübinger Biotech-Unternehmen Curevac auf die Forschung. …See details»